Published in Blood Weekly, May 20th, 2004
A "modified Japanese capecitabine regimen as first-line treatment for advanced/ metastatic colorectal cancer" was evaluated in a phase II study. "Sixty patients received oral capecitabine 828 mg/m2 twice daily for 3 weeks every 4 weeks," wrote researchers in Japan.
"In the 56 efficacy-evaluable patients, the overall response rate was 26.8% (95% Cl 15.8-40.3%) and 21 patients (37.5%) had stable disease. The median duration of response and overall survival times were 7.4 months (range 4.3-13.8) and 17.6 months (95% CI 14.1-20.5), respectively," J. Sakamoto and colleagues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.